pre-filled syringes containing 11700 anti-Xa IU/mL, (2500 anti-Xa IU/0.2 mL, 3500 anti-Xa IU/0.3 mL and 4500 antiXa IU/0.4 mL)
multi dose vials containing 10 000 anti-Xa IU/mL in 2 mL vials
Indication: prevention of postoperative thromboembolism
Tinzaparin is an addition to the choice of low molecular weight heparins. These products are fragments of heparin which differ in their method of production. Tinzaparin is produced by deploymerisation of heparin obtained from the intestine of pigs.
The low molecular weight heparins cannot be interchanged and the clinical effect may not be directly related to the antiXa activity. The efficacy of tinzaparin in orthopaedic surgery has only been evaluated in patients undergoing elective hip replacement.
The adverse effect profile is similar to that of conventional heparin. A reduced risk of bleeding with low molecular heparins has not been demonstrated. As tinzaparin comes in a variety of dose forms, great care should be taken to ensure the patient receives the recommended dose.